Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma

Inclusion Criteria: * Cytologically or histologically confirmed adenocarcinoma of the exocrine pancreas * Disease non-resectable and locally advanced or metastatic * Measurable disease or evaluable disease i.e. tumor marker CA19-9 at baseline ≥ 1.5 x upper limit of normal (ULN) * Age \>18 years * Karnofsky performance status ≥ 60% * Life expectancy of at least 3 months * Written informed consent * Willing and able to comply with the protocol for the duration of the study Exclusion Criteria: * Prior chemotherapy for pancreatic cancer * Prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of inclusion * Known CNS metastases at the time of enrollment * Neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl * Serum creatinine \> 1.25 x ULN * ASAT, ALAT and alkaline phosphatase \> 2.5 ULN or \> 5 ULN in the presence of liver metastasis, Bilirubin \> 1.5 ULN (after treatment of obstructive jaundice eg. stent) * Pregnant or breast feeding women (women of childbearing potential must have a negative pregnancy test at baseline) * Men and women of reproductive potential who are not using an effective method of contraception * Clinically significant cardiac disease (NYHA III-IV) or myocardial infarction within the last 12 months * Neurological disease with dys-/paraesthesias \> grade 1 according to NCI CTC * Any serious concomitant disorder incompatible with the trial (in the judgement of the investigator) * Psychiatric disability thought to be clinically significant in the opinion of the investigator precluding informed consent or interfering with compliance